Corilagin alleviates intestinal ischemia/reperfusion-induced intestinal and lung injury in mice via inhibiting NLRP3 inflammasome activation and pyroptosis

Intestinal ischemia reperfusion (II/R) is a clinical emergency that frequently occurs in a variety of clinical conditions. Severe intestinal injury results in the release of cytotoxic substances and inflammatory mediators which can activate local inflammatory response and bacterial translocation. Th...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 1060104
Main Authors Li, Wenlian, Yang, Kejia, Li, Bin, Wang, Yunxiang, Liu, Jing, Chen, Dapeng, Diao, Yunpeng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.11.2022
Subjects
corilagin
intestine
ischemia-reperfusion
lung
NLRP3
Pharmacology
pyroptosis
lung
corilagin
pyroptosis
NLRP3
intestine
ischemia-reperfusion
Online AccessGet full text

Cover

More Information
Summary:Intestinal ischemia reperfusion (II/R) is a clinical emergency that frequently occurs in a variety of clinical conditions. Severe intestinal injury results in the release of cytotoxic substances and inflammatory mediators which can activate local inflammatory response and bacterial translocation. This triggers multi-organ failure, including lung injury, which is a common complication of II/R injury and contributes to the high mortality rate. Corilagin (Cor) is a natural ellagitannin found in a variety of plants. It has many biological and pharmacological properties, including antioxidant, anti-inflammatory and anti-apoptosis activities. However, no studies have evaluated the effects and molecular mechanisms of Cor in alleviating II/R-induced intestinal and lung damage. In this study, Cor was found to significantly alleviate II/R-induced pathological damage, inflammatory response, oxidative stress, NLRP3 inflammasome activation, and pyroptosis in intestinal and lung tissues both in vivo and in vitro . Further, Cor inhibited the NLRP3 inflammasome activation and pyroptosis in RAW264.7 and MLE-12 cells induced by LPS/nigericin and that in IEC-6 cells induced by nigericin, indicating an amelioration of Cor in II/R-induced intestinal and lung injury via inhibiting NLRP3 inflammasome activation and pyroptosis. Thus, Cor might be a potential therapeutic agent for II/R-induced inflammation and tissue injury.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Zhen Qiu, Renmin Hospital of Wuhan University, China
Reviewed by: Shiyu Song, Nanjing University, China
Elisa Palladino, Virginia Commonwealth University, United States
These authors have contributed equally to this work
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Edited by: Fuchun Yang, College of Medicine, University of Cincinnati, United States
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.1060104